Cambridge Investment Research Advisors’s iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038 JO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio JO Stock Details JO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,286	Closed	-$649K	–	2294
2018 Q1	$649K	Sell	45,286 -2,450	-5%	-$36.8K	0.01%	1191
2017 Q4	$749K	Buy	+47,736	New	+$762K	0.01%	1063

Other funds holding JO

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Cambridge Investment Research Advisors's JO Position: Q2 2018 in Review

Cambridge Investment Research Advisors sold out of iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038 (JO) in Q2 2018, closing a stake of 45,286 shares — an estimated $649K sold.

Cambridge Investment Research Advisors first reported a position in JO in Q4 2017 and held it in 2 quarters. The position peaked at $749K in Q4 2017. 3 funds tracked by Wall St. Rank hold JO as of Q2 2018.

Cambridge Investment Research Advisors reported no remaining iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038 position as of Q2 2018 after selling out during the quarter.
Cambridge Investment Research Advisors sold 45,286 iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038 shares in Q2 2018, an estimated $649K.
Cambridge Investment Research Advisors first reported a position in iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038 in Q4 2017 and held it in 2 quarters.
Cambridge Investment Research Advisors's iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038 position peaked at $749K in Q4 2017.
3 funds tracked by Wall St. Rank held iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038 as of Q2 2018.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.